Examines cognitive decline related to cardiovascular disease risk in adults, suggesting monitoring may help cognitive function.
Background Cardiovascular disease (CVD) is a major risk factor for cognitive decline and dementia. We examined whether a higher atherosclerotic cardiovascular disease (ASCVD) risk is associated with faster cognitive decline in Project FRONTIER, a rural cohort. Methods Participants were aged ≥40 years without baseline CVD and completed two study visits. Primary outcomes were the RBANS Total Score and its domains; secondary outcomes were Executive Interview 25, verbal fluency, Clock Drawing Test (CLOX), and Trail Making Test (TMT) A and B. Primary exposure was the 10-year ASCVD risk per AHA PREVENT equations. We fitted Bayesian mixed-effects models to estimate the interaction between time (in years) and ASCVD risk, adjusting for covariates using brms package in R. Results We analyzed data of 383 participants (age 57.74 ± 11.4 years; 75.5 % female; 59.8 % Hispanic; median follow-up 3.00 years, IQR: 2.67–3.64). The time×ASCVD risk interaction for RBANS Total was credibly negative (β = −1.22 points/year per 10 % higher risk, 95 % CrI −1.87 to −0.58). Strongest domain-specific effects were for attention (β = −1.25; 95 % CrI −2.14 to −0.37) and delayed memory (β = −1.36; 95 % CrI −2.16 to −0.05). CLOX suggested a credibly negative interaction (β = −0.39; 95 % CrI −0.62 to −0.16), and TMT-A showed a credibly positive interaction (β = +2.85 s/year; 95 % CrI 1.28 to 4.41). Discussion In this rural cohort, a higher 10-year ASCVD risk was associated with faster decline in global cognition, particularly attention and delayed memory, supporting the potential value of cardiovascular risk monitoring and modification to preserve cognitive function.
No takes yet. Share an insight, caveat, or question.
Dhanasekara et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: